Home
Per Øyvind Enger's picture

Per Øyvind Enger

Professor
  • E-mailPer.Enger@uib.no
  • Phone+47 55 58 63 47+47 55 58 63 73
  • Visitor Address
    Jonas Lies vei 91
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2019. Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers. 1-25.
  • 2019. Platelet‐derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. Glia. 1-10.
  • 2019. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • 2019. Astrocytes enhance glioblastoma growth. Glia. 1-12.
  • 2018. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study. Journal of Neurosurgery. 71-83.
  • 2018. Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. iScience.
  • 2017. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. BMC Cancer. 1-13.
  • 2017. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. OncoTarget. 12145-12157.
  • 2017. Membrane-depolarizing channel blockers induce selective glioma cell death by impairing nutrient transport and unfolded protein/amino acid responses. Cancer Research. 1741-1752.
  • 2016. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. Journal of Neuro-Oncology.
  • 2016. Quality of life is maintained using Gamma Knife radiosurgery: A prospective study of a brain metastases patient cohort. Journal of Neurosurgery. 708-725.
  • 2016. Identification of a natural killer cell receptor allele that prolongs survival of cytomegalovirus-positive glioblastoma patients. Cancer Research. 5326-5336.
  • 2016. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro-Oncology. 1644-1655.
  • 2016. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. BMC Cancer. 12 pages.
  • 2015. Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc<sup>-</sup>, leading to glutathione depletion. Oncogene. 5951-5959.
  • 2014. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells . Cancer Medicine. 812-824.
  • 2014. Rapid adherence to collagen IV enriches for tumour initiating cells in oral cancer. European Journal of Cancer. 3262-3270.
  • 2014. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. Journal of Immunology. 6192-6206.
  • 2014. Increased Survival Using Delayed Gamma Knife Radiosurgery for Recurrent High-Grade Glioma: A Feasibility Study . World Neurosurgery. e623-e632.
  • 2014. Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma. PLOS ONE.
  • 2014. Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma. PLOS ONE. 12 pages.
  • 2014. A novel GFP nude rat model to investigate tumor-stroma interactions. Cancer Cell International.
  • 2014. A co-culture model with brain tumor-specific bioluminescence demonstrates astrocytes-induced drug resistance in glioblastoma. Journal of Translational Medicine.
  • 2013. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. OncoTarget. 1527-1546.
  • 2013. Gamma knife surgery of colorectal brain metastases: a high prescription dose of 25 Gy may improve growth control. World Neurosurgery. 525-536.
  • 2013. Gamma knife surgery as monotherapy with clinically relevant doses prolongs survival in a Human GBM Xenograft Model. Biomedical research. 9 pages.
  • 2013. Establishment of a novel dsRed NOD/Scid mouse strain to investigate the host and tumor cell compartments. Cancer Investigation. 221-230.
  • 2013. Elevated CD3(+) and CD8(+) tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. Journal of Neuroimmunology. 71-83.
  • 2013. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathologica. 683-698.
  • 2012. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 6662-6667.
  • 2012. Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation. BMC Cancer. 10 pages.
  • 2012. Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurgery. 658-669.
  • 2011. Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. PLOS ONE. 14 pages.
  • 2011. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide. BMC Cancer.
  • 2011. Gamma Knife Surgery of Colorectal Brain Metastases: A High Prescription Dose of 25 Gy May Improve Growth Control. World Neurosurgery. 684-691.
  • 2011. Gamma Knife Surgery in Brain Melanomas: Absence of Extracranial Metastases and Tumor Volume Strongest Indicators of Prolonged Survival. World Neurosurgery. 684-691.
  • 2011. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathologica. 495-510.
  • 2010. alpha B-Crystallin Is Elevated in Highly Infiltrative Apoptosis-Resistant Glioblastoma Cells. American Journal of Pathology. 1618-1628.
  • 2010. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Research. 4274-4279.
  • 2010. Gamma knife surgery of meningiomas involving the cavernous sinus: long-term follow-up of 100 patients. Neurosurgery. 661-669.
  • 2009. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathology and Applied Neurobiology. 380-393.
  • 2009. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer.
  • 2008. Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics. NMR in Biomedicine. 830-838.
  • 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • 2008. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer. 761-768.
  • 2008. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. The FASEB Journal. 3120-3128.
  • 2007. Human glioblastoma biopsy spheroids xenografted into the nude rat brain show growth inhibition after stereotactic radiosurgery. Journal of Neuro-Oncology. 1-10.
  • 2006. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Research. 9895-9902.
  • 2006. Primary glioma spheroids maintain tumourogenicity and essential phenotypic traits after cryopreservation. Neuropathology and Applied Neurobiology. 419-427.
  • 2006. NG2 expression regulates vascular morphology and function in human brain tumours. NeuroImage. 965-976.
  • 2006. Antitumor efficacy improved by local delivery of species-specific endostatin. Journal of Neurosurgery. 118-128.
  • 2006. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 16466-16471.
  • 2005. NG2 expression regulates vascular morphology and function in human brain tumours. NeuroImage. 965-976.
  • 2002. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in the central nervous system by sequestering angiostatin. The FASEB Journal. 586-588.
  • 2001. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nature Biotechnology. 29-34.
Lecture
  • 2018. Synthesis of targeting molecules as tracers for PET and anticancer pro-drugs: investigation of tumor drug distribution.
  • 2018. Synthesis of targeting molecules as tracers for PET and anticancer pro-drugs: investigation of tumor drug distribution.
Academic lecture
  • 2019. Synthesis of targeting molecules : PET and therapeutics.
  • 2018. Synthesis of targeting molecules as tracers for PET and anticancer pro-drugs: investigation of tumor drug distribution.
  • 2018. Synthesis of targeting molecules as tracers for PET and anticancer pro-drugs: investigation of tumor drug distribution .
  • 2002. Endostatin Gene Transduction of Glioma Cells Modifies Brain Tumor Development: Assessment by Magnetic Resonance Imaging.
Masters thesis
  • 2019. Sulfasalazine analogues to overcome radioresistance in cancer.
  • 2014. POU3f2 in human gliomas -Expression pattern and functional role.
  • 2011. Impact of hypoxia on the expression of cell line markers and behavior of cultured glioma cell lines.
  • 2011. GROWTH OF GLIOBLASTOMA XENOGRAFTS IN THE BRAINS OF NOD/SCID MICE FOLLOWING ADMINISTRATION OF A DEMYELINATING AGENT.
  • 2010. Aquaporin 1 and Aquaporin 4 in Glioblastoma Multiforme.
  • 2008. Involvement of E2F5 in brain tumour progression.
Doctoral dissertation
  • 2015. Targeting survival signalling pathways in glioblastoma. Preclinical studies of sulfasalazine, dactolisib and buparlisib.
Abstract
  • 2013. Sulfasalazine sensitizes glioblastoma cells to radiation treatment. Neuro-Oncology. 239-239.
  • 2013. Oct 7 IS EXPRESSED IN HUMAN GLIOMAS AND CORRELATES WITH MALIGNANCY GRADE. Neuro-Oncology. 20-21.
  • 2013. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Neuro-Oncology. 6-6.
  • 2013. COMBINED ANTI-ANGIOGENIC AND ANTI-INVASIVE TREATMENT OF ORTHOTOPICALLY ENGRAFTED HUMAN GBM XENOGRAFTS. Neuro-Oncology. 43-43.
  • 2013. ACTIVATION OF THE PROTOTYPICAL SFK c-Src PROMOTES ANGIOGENESIS OF HUMAN GLIOBLASTOMA. Neuro-Oncology. 3-3.
  • 2012. HYPOXIA INDUCES CELL PROLIFERATION, EXPRESSION OF ANGIOGENIC FACTORS, AND PRIMITIVE NEURONAL MARKERS IN NORMAL GLIAL CELLS. Neuro-Oncology. 11-11.
  • 2012. Early MRI findings of targeting the NG2 proteoglycan in GBM. The FASEB Journal. 1 pages.
  • 2011. TUMOR-ASSOCIATED GLIAL CELLS PROMOTE GROWTH OF GBM XENOGRAFTS IN EGFP NOD/SCID MICE. Neuro-Oncology. 55-55.
  • 2011. Separate analysis of the cancer and stroma cell populations from orthotopically implanted tumor biopsies in eGFP scid mice. Clinical and Experimental Metastasis. 203-203.
  • 2010. THERAPEUTIC TARGETING OF THE NG2 PROTEOGLYCAN WITH MAB 9.2.27 AND ADOPTIVELY TRANSFERRED NK CELLS LYSES HUMAN GLIOBLASTOMA MULTIFORME IN VIVO. Neuro-Oncology. 9-9.
  • 2010. SULFASALAZINE SENSITIZES GLIOBLASTOMA CELLS TO RADIATION TREATMENT. Neuro-Oncology. 109-109.
  • 2010. NG2 PROMOTES RESISTANCE TO IONIZING RADIATION BY ELEVATED PEROXIREDOXIN-1 AND DNA DAMAGE RESPONSE IN GLIOBLASTOMA MULTIFORME. Neuro-Oncology. 8-8.
  • 2009. Targeting the tumor stroma: a novel therapeutic strategy based on separate analysis of the malignant and stromal cell compartments in brain tumors. Neuro-Oncology. 221-222.
  • 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 965-965.
  • 2009. PHENOTYPIC MODULATION OF EXPERIMENTAL GLIOMAS: PROGRESSION FROM GLIOMATOSIS CEREBRI-LIKE LESIONS TO GLIOBLASTOMA. Neuro-Oncology. 897-897.
  • 2009. CD133-NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS DISPLAY TUMORIGENICITY IN VIVO. Neuro-Oncology. 917-917.
  • 2008. Human glioblastoma tissue engraftment in immunocompetent rodent hosts. Neuro-Oncology. 815-815.
  • 2008. Complete separation and phenotyping of the tumor-host cellular compartments in tumor bearing nod/scid mice. Neuro-Oncology. 1148-1148.
  • 2008. COMPLETE SEPARATION AND PHENOTYPING OF THE TUMOR-HOST CELLULAR COMPARTMENTS IN TUMOR-BEARING NOD/SCID MICE. Neuro-Oncology. 853-854.
  • 2008. CD133-NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS DISPLAY TUMORGENICITY IN VIVO. Neuro-Oncology. 778-778.
  • 2004. Forced differentiation suppresses the proliferative rate of cancer cells in brain tumours. Neuro-Oncology.
  • 2004. Angiogenesis-independent growth by brain tumor cells exhibiting cancer stem cell properties. Neuro-Oncology. 309-309.
Poster
  • 2011. Therapeutic Targeting of NG2 Proteoglycan with MAb & Pre-Armed NK Cells in Human GMB Evaluated with Dynamic Enhanced & Diffusion Weighted MRI in Rats.
  • 2009. Highly infiltrative brain tumors show reduced chemosensitivity associated with a stem cell-like phenotype.
  • 2003. Phenotyping by MRI: NG2 Receptor Status Modifies Human Glioblastoma Development.
  • 2003. NG2 receptor status modifies human glioblastoma development: Assessment by MRI.
  • 2002. Endostatin gene trandsuction of glioma cells modifies brain tumor development: Assessment by MRI.
Academic literature review
  • 2017. Drug repurposing in cancer. 74-91.
  • 2010. Cancer stem cells in the central nervous system - a critical review. 8255-8258.
  • 2007. Lymphangiogenesis in colorectal cancer - Prognostic and therapeutic aspects. 1401 -1409.
Medical Student Research Thesis
  • 2015. Tumour-associated glial cells promote the Growth of GBM xenografts.

More information in national current research information system (CRIStin)